Mr. Southwell joined Inotek in August 2014 as President and Chief Executive Officer. Mr. Southwell brings to Inotek over 20 years of specialty pharmaceuticals and biotechnology experience, including IPOs, follow-on financings, mergers and acquisitions and corporate leadership.
Most recently, Mr. Southwell served as Executive Vice President and Chief Financial Officer of Human Genome Sciences during the approval and launch of the novel biologic treatment for lupus, Benlysta®, and up until its acquisition by Glaxo Smithkline. Prior to his appointment as CFO, he served on the Board of Directors of Human Genome Sciences. Mr. Southwell’s career started in investment banking at Lehman Brothers, where among other financing and M&A transactions he led the IPO of Sepracor Inc. He subsequently joined Sepracor as EVP, Chief Financial Officer, a position he held for fourteen years during which time Sepracor raised over $2 billion in equity and convertible security financings, and developed, launched and commercialized two novel medicines for asthma and insomnia. Following his time at Sepracor, he mounted a funded take-private bid for the company with the company’s founder, which led to its acquisition by Dainippon Sumitomo in 2009.
Mr. Southwell serves on the boards of PTC Therapeutics and and on the Board of Overseers of the Tuck School of Business at Dartmouth College. His previous board memberships include Biosphere Medical, Inc. (acquired) as Chairman and THL Credit, Inc. He holds an MBA from the Tuck School, and a BA is from Rice University.
Dr. Baumgartner joined Inotek in 2007 as Executive Vice President and Chief Medical Officer and brings to the company more than 20 years of scientific, drug and biotechnology development experience, as well as, clinical experience as a practicing Pulmonary and Critical Care physician. He has undertaken all phases of drug and technology development, and has been directly involved in filing INDs and NDAs, with their requisite face-to-face regulatory meetings, and has been awarded several biotechnology patents.
More recently, Dr. Baumgartner served as VP of Clinical Research, and Therapeutic Area Head for Respiratory and Immunology, at Sepracor Inc. where he led the development and filing of multiple NDAs, including two approved after the first cycle of review. Dr. Baumgartner began his industry experience at Merck Research Laboratories, where as Director of Clinical Research he worked with both early and late stage assets. He received his M.D. from Pennsylvania State University, Internal Medicine training at the University of Michigan Hospitals, and Pulmonary and Critical Care training at the Johns Hopkins University Hospital. After finishing his medical training, Dr. Baumgartner joined the Laboratory of Molecular Immunology at the National Institutes of Health (NIH, Bethesda) and undertook basic science research on inflammation and mechanisms of inflammatory cell-signaling.
Mr. Ritter initiated consulting work with Inotek Pharmaceuticals in June of 2014 and became our Vice President, Finance and Chief Accounting Officer in August of 2014. Mr. Ritter has 25 years of experience in the pharmaceutical industry. From May 2011 to November 2013, Mr. Ritter was Senior Vice President, Finance, and Chief Accounting Officer of Coronado Biosciences, Inc. From September 2009 until May 2011 he was an independent financial consultant and served as a financial consultant to Helicos BioSciences Corporation. From 1994 to 2009, Mr. Ritter was the Senior Vice President, Finance and Chief Accounting Officer at Indevus Pharmaceuticals, Inc. until the sale of the company to Endo Pharmaceuticals. Mr. Ritter has a B.A. from Syracuse University and an MBA from Babson College Graduate School of Business Administration.
Claudine Prowse, Ph.D., joined Inotek in 2015 as Vice President, Strategy and Investor Relations Officer (IRO). Dr. Prowse has more than 15 years of experience in the biotechnology industry spanning small, mid and large cap biotech companies. She served in various capacities including Vice President, Investor Relations and Planning at Biogen, Vice President and Product Manager of Medacorp, Leerink Swann; Vice President, Investor Relations at Human Genome Sciences; and Executive Director, Corporate Development, Isis Pharmaceuticals.
She holds a B.S. in Biomedical Engineering from the University of California, San Diego (UCSD) School of Engineering and a Ph.D. in Biomedical Sciences from the UCSD School of Medicine.
Dr. Rich joined Inotek in 2015 as Vice President, Medical Affairs and Clinical Development and brings more than 20 years of Ophthalmology and clinical/product development experience spanning clinical practice, clinical development, product development, medical affairs and regulatory strategy. He has experience in all phases/aspects of both clinical and product development including being directly involved in the submission and approval of multiple drugs and medical devices in the US and Europe.
Prior to joining Inotek Dr. Rich held several senior management positions at Alcon Laboratories, including Global Head Clinical Trial Management, Pharmaceuticals and Therapeutic Unit Head, Intraocular Lens Research and Development. Immediately prior to Alcon Dr. Rich held several leadership positions at Quintiles Transnational including Senior Director, Integrated Patient and Site Strategies and Senior Medical Director and Head, Ophthalmology Center of Excellence. Dr. Rich received his undergraduate degree from Case Western Reserve University and his M.D. degree and Ophthalmology training at the University of North Carolina at Chapel Hill. While in clinical practice Dr. Rich received his MBA from Regis University and while at Quintiles he furthered his medical leadership training by receiving his Certified Physician Executive certification from the American Association for Physician Leadership.